AI Engines For more Details: Perplexity Kagi Labs You
Chronic Pain: One of the most well-known uses of medical marijuana is for the management of chronic pain conditions such as neuropathic pain, arthritis, and fibromyalgia. Both THC and CBD have been shown to have analgesic properties, which can help alleviate pain and improve quality of life for individuals with chronic pain.
Nausea and Vomiting: Medical marijuana, particularly strains high in THC, has been used to alleviate nausea and vomiting in cancer patients undergoing chemotherapy, as well as individuals with other medical conditions that cause nausea, such as HIV/AIDS and multiple sclerosis.
Muscle Spasticity: Marijuana may help reduce muscle spasticity and stiffness in conditions such as multiple sclerosis (MS) and spinal cord injury. Both THC and CBD have muscle-relaxant properties, which can lead to improved mobility and function for individuals with these conditions.
Appetite Stimulation: Marijuana is known to increase appetite, a phenomenon often referred to as "the munchies." This effect can be beneficial for individuals with conditions that cause appetite loss or cachexia, such as cancer, HIV/AIDS, and eating disorders.
Epilepsy: CBD, in particular, has shown promise in the treatment of certain types of epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome. Clinical trials have demonstrated that CBD can reduce the frequency and severity of seizures in some individuals with these conditions.
Anxiety and Depression: While high doses of THC can exacerbate anxiety and paranoia in some individuals, low to moderate doses and certain strains of marijuana may have anxiolytic (anxiety-reducing) and antidepressant effects. CBD has also been studied for its potential to reduce anxiety and improve mood.
Sleep Disorders: Marijuana may help improve sleep quality and reduce sleep disturbances in individuals with insomnia and other sleep disorders. THC can have sedative effects, while CBD may help regulate sleep-wake cycles and promote relaxation.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.4 | -0.4 | |
ADHD | 0.8 | 0.6 | 0.33 |
Allergic Rhinitis (Hay Fever) | 0.3 | 0.6 | -1 |
Allergies | 1.1 | 1.1 | |
Allergy to milk products | 0.8 | 0.4 | 1 |
Alopecia (Hair Loss) | 0.2 | 0.2 | |
Alzheimer's disease | 0.9 | 1.1 | -0.22 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.4 | -1 |
Ankylosing spondylitis | 1.4 | 1.3 | 0.08 |
Anorexia Nervosa | 0.3 | -0.3 | |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 0.6 | 0.9 | -0.5 |
Atherosclerosis | 0.4 | -0.4 | |
Atrial fibrillation | 1.1 | 0.5 | 1.2 |
Autism | 1.8 | 1.5 | 0.2 |
Bipolar Disorder | 0.7 | 0.4 | 0.75 |
Brain Trauma | 0.8 | 0.3 | 1.67 |
Carcinoma | 0.5 | 0.9 | -0.8 |
Celiac Disease | 0.9 | 0.3 | 2 |
Cerebral Palsy | 0.4 | 0.7 | -0.75 |
Chronic Fatigue Syndrome | 1.2 | 0.5 | 1.4 |
Chronic Kidney Disease | 0.3 | 0.4 | -0.33 |
Chronic Lyme | 0.3 | -0.3 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | -0.4 | |
Chronic Urticaria (Hives) | 0.6 | 0.4 | 0.5 |
Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
Colorectal Cancer | 0.9 | 0.8 | 0.13 |
Constipation | 2.3 | 2.3 | |
Coronary artery disease | 0.4 | -0.4 | |
COVID-19 | 3.2 | 3.4 | -0.06 |
Crohn's Disease | 1.3 | 1.3 | 0 |
cystic fibrosis | 0.3 | -0.3 | |
Depression | 2.2 | 1.5 | 0.47 |
Eczema | 0.4 | 0.2 | 1 |
Endometriosis | 0.5 | 0.6 | -0.2 |
Epilepsy | 1.1 | 0.9 | 0.22 |
Fibromyalgia | 0.2 | 0.5 | -1.5 |
Functional constipation / chronic idiopathic constipation | 3.3 | 1.1 | 2 |
gallstone disease (gsd) | 0.2 | -0.2 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 0.4 | 1.75 |
Generalized anxiety disorder | 0.3 | -0.3 | |
Glioblastoma | 0.4 | 0.4 | |
Gout | 0.4 | 0.4 | |
Graves' disease | 0.3 | 0.8 | -1.67 |
Halitosis | 0.3 | 0.4 | -0.33 |
Hashimoto's thyroiditis | 0.7 | 0.3 | 1.33 |
Hidradenitis Suppurativa | 0.4 | -0.4 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.5 | 0.5 | |
hypercholesterolemia (High Cholesterol) | 0.4 | -0.4 | |
hyperglycemia | 0.2 | 0.3 | -0.5 |
hypertension (High Blood Pressure | 0.7 | 1.1 | -0.57 |
Hypothyroidism | 0.2 | -0.2 | |
Hypoxia | 0.7 | 0.7 | |
IgA nephropathy (IgAN) | 0.6 | 0.7 | -0.17 |
Inflammatory Bowel Disease | 0.7 | 0.9 | -0.29 |
Insomnia | 0.7 | 2 | -1.86 |
Intelligence | 1.2 | 1.2 | |
Intracranial aneurysms | 0.3 | 0.3 | |
Irritable Bowel Syndrome | 1.4 | 1.3 | 0.08 |
Liver Cirrhosis | 0.7 | 0.9 | -0.29 |
Long COVID | 2.3 | 1.5 | 0.53 |
Lung Cancer | 0.2 | 0.2 | |
ME/CFS with IBS | 0.3 | -0.3 | |
ME/CFS without IBS | 0.3 | -0.3 | |
Menopause | 0.2 | 0.2 | 0 |
Metabolic Syndrome | 1.6 | 2.1 | -0.31 |
Mood Disorders | 2.4 | 1.9 | 0.26 |
Multiple Sclerosis | 0.6 | 1.5 | -1.5 |
Multiple system atrophy (MSA) | 0.4 | -0.4 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 1.1 | -0.1 |
Obesity | 1.3 | 1.1 | 0.18 |
obsessive-compulsive disorder | 1.6 | 0.3 | 4.33 |
Osteoarthritis | 0.3 | 0.3 | |
Osteoporosis | 0.5 | 0.8 | -0.6 |
Parkinson's Disease | 1 | 0.6 | 0.67 |
Polycystic ovary syndrome | 0.7 | 1.2 | -0.71 |
primary biliary cholangitis | 0.2 | -0.2 | |
Psoriasis | 1 | 0.7 | 0.43 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 1.9 | -0.27 |
Schizophrenia | 1.1 | 0.8 | 0.38 |
scoliosis | 0.4 | 0.4 | |
Sjögren syndrome | 0.4 | 1.1 | -1.75 |
Sleep Apnea | 0.3 | -0.3 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | -0.4 | |
Stress / posttraumatic stress disorder | 0.3 | 0.5 | -0.67 |
Systemic Lupus Erythematosus | 1.9 | 0.8 | 1.37 |
Tic Disorder | 1.6 | 0.6 | 1.67 |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 1.3 | 1 | 0.3 |
Type 2 Diabetes | 1.8 | 2.1 | -0.17 |
Ulcerative colitis | 1.6 | 1.6 | 0 |
Unhealthy Ageing | 1.1 | 1.1 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.